BioMérieux
T2 Biosystems Pathogen Detection Patent Upheld in Europe
French diagnostics maker BioMérieux and other undisclosed firms had filed an opposition to the patent in May 2023.
BioMérieux Q2 Revenues Rise 8 Percent
The firm raised its full-year 2024 guidance to sales growth at constant exchange rates of 8 percent to 10 percent, up from previous guidance of 6 percent to 8 percent growth.
At the ADLM annual meeting, firms said they see game-changing opportunities for platforms that provide the right combination of clinical utility and convenience.
BioMérieux Respiratory/Sore Throat Mini Panel Gets FDA Special 510(k) Clearance, CLIA Waiver
The firm said that it expects its SpotFire Respiratory/Sore Throat (R/ST) Panel Mini test to be available in the US in the third quarter of 2024.
The company plans to release Ampore-TB for research use only later this year, followed by regulatory submissions in the US and Europe.
Apr 12, 2024
Oct 26, 2023
BioMérieux Q3 Revenues Dip Slightly
Sep 1, 2023
BioMérieux Q2 Revenues Rise 5 Percent
Apr 27, 2023